– March 1, 2004
March 1, 2004
View Issues
-
More on Lymphoma Treatment in the Elderly: Results from Korea
In a series from Korea, treatment outcomes for older (age older than 60 years) patients with diffuse large-cell lymphoma were analyzed with particular focus on dose intensity of doxorubicin. Although, overall, older patients did not achieve the same level of complete response, for those who were able to maintain doxorubicin dose intensity, response rates were comparable to younger patients. -
Oral Capecitabine as an Alternative to IV 5-fluorouracil-Based Adjuvant Therapy for Colon Cancer: Safety Results of a Randomized, Phase III Trial
Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer. -
The Significance of Imatinib Mesylate (Gleevec®)-Induced Cytopenias in Patients with Chronic-Phase CML
In a series of chronic-phase CML patients who had previously been treated with interferon and who subsequently received imatinib mesylate, the appearance of myelosuppression (Grade > 3 neutropenia or thrombocytopenia) was associated with significantly less frequent major or complete cytogenetic responses. -
Temozolomide (Temodur®) Treatment and Immunodeficiency in Melanoma Patients
Temozolomide has been used for the treatment of melanoma with effects comparable to DTIC, and regimens are currently under development that involve more extensive administration. In this report from Memorial Sloan Kettering, patients treated on a daily schedule for 6 weeks or more before a treatment break were observed to develop significant lymphopenia and a higher-than-expected incidence of opportunistic infections. -
Enthusiasm for Cancer Screening in the United States
Most Americans believe that screening tests for cancer save lives and that it is irresponsible not to undergo recommended periodic screening. The presence of a large market for cancer screening may make Americans vulnerable to unproven and unnecessary testing. -
Myometrial Invasion and the Tumor-Free Distance from the Uterine Serosa in Endometrial Cancer?
TFD as a single measurement carries significant prognostic importance in women with comprehensively staged endometrial cancer. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: Sinus and Allergy Health Partnership Releases New Guidelines for Treatment of Bacterial Rhinosinusitis